Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study

Peer Review reports

Original Submission
27 Apr 2022	Submitted	Original manuscript
6 May 2022	Author responded	Author comments - Xiaoyong Zeng
Resubmission - Version 2
6 May 2022	Submitted	Manuscript version 2
30 May 2022	Reviewed	Reviewer Report
13 Jul 2022	Reviewed	Reviewer Report
18 Jul 2022	Author responded	Author comments - Xiaoyong Zeng
Resubmission - Version 3
18 Jul 2022	Submitted	Manuscript version 3
Publishing
29 Jul 2022	Editorially accepted
20 Aug 2022	Article published	10.1186/s12894-022-01083-8

Back to article page